- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Janux Therapeutics Inc (JANX)
Assess today's live Janux Therapeutics Inc (JANX) share price, performance and insights using our live NASDAQ: JANX stock exchange data.
Analyse the historical data and Janux Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Janux Therapeutics share price buy/sell indicators using real-time data (or discuss the Janux Therapeutics (JANX) stock price today with other investors in the Janux Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ JANX share price (ISIN: US47103J1051) to enhance your trading decisions with our free investment tools and resources.
What Is the Janux Therapeutics Inc Share Price Today?
The Janux Therapeutics share price today is 14.12.
What Is the Stock Symbol for Janux Therapeutics Inc
The stock symbol (or 'ticker') for Janux Therapeutics Inc is "JANX."
What Stock Exchange Does Janux Therapeutics Inc Trade On?
Janux Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Janux Therapeutics Inc a Good Stock to Buy?
Determining whether Janux Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Janux Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Janux Therapeutics share price buy/sell indicators using real-time data (or discuss the Janux Therapeutics (JANX) stock price today with other investors in the Janux Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ JANX share price (ISIN: US47103J1051) to enhance your trading decisions with our free investment tools and resources.
What Is the Janux Therapeutics Inc Share Price Today?
The Janux Therapeutics share price today is 14.12.
What Is the Stock Symbol for Janux Therapeutics Inc
The stock symbol (or 'ticker') for Janux Therapeutics Inc is "JANX."
What Stock Exchange Does Janux Therapeutics Inc Trade On?
Janux Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Janux Therapeutics Inc a Good Stock to Buy?
Determining whether Janux Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.82
14.16
52 wk Range
13.76
61.59
JANX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.8214.16
52 wk Range
13.7661.59
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
JANX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
65.12
Upside
+361.17%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
8 analysts have revised their earnings upwards for the upcoming period
- Form 144 JANUX THERAPEUTICS For: 2 December
- Investing.com
- Form 144 JANUX THERAPEUTICS For: 15 December
- Investing.com
- Form 144 JANUX THERAPEUTICS For: 8 December
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Janux Therapeutics Company Profile
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Compare JANX to Peers and Sector
Metrics to compare | JANX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJANXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.3x | −3.2x | −0.6x | |
PEG Ratio | 0.20 | 0.13 | 0.00 | |
Price/Book | 0.9x | 2.8x | 2.6x | |
Price / LTM Sales | 84.9x | 376.4x | 3.2x | |
Upside (Analyst Target) | 303.7% | 100.7% | 41.8% | |
Fair Value Upside | Unlock | −1.1% | 5.1% | Unlock |
Analyst Ratings
18 Buy
1 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 65.12
(+361.17% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-0.39 / -0.62
Revenue / Forecast
10.00M / 2.88M
People Also Watch
FAQ
What Is the Janux Therapeutics (JANX) Share Price Today?
The live Janux Therapeutics share price today is 14.12
What Stock Exchange Does Janux Therapeutics (JANX) Trade On?
Janux Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Janux Therapeutics?
The stock symbol (also called a 'ticker') for Janux Therapeutics is "JANX."
What Is the Current Janux Therapeutics Market Cap?
As of today, Janux Therapeutics market capitalisation is 849.29M.
What Is Janux Therapeutics's (JANX) Earnings Per Share (TTM)?
The Janux Therapeutics EPS is currently -1.68 (Trailing Twelve Months).
When Is the Next Janux Therapeutics Earnings Date?
Janux Therapeutics's next earnings report will be released on 06 Mar 2026.
Is JANX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Janux Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Janux Therapeutics Stock Split?
Janux Therapeutics has split 0 times. (See the JANX stock split history page for full effective split date and price information.)
How Many Employees Does Janux Therapeutics Have?
Janux Therapeutics has 109 employees.
What is the current trading status of Janux Therapeutics (JANX)?
As of 24 Dec 2025, Janux Therapeutics (JANX) is trading at a price of 14.12, with a previous close of 14.09. The stock has fluctuated within a day range of 13.82 to 14.16, while its 52-week range spans from 13.76 to 61.59.
What Is Janux Therapeutics (JANX) Price Target According to Analysts?
The average 12-month price target for Janux Therapeutics is USD65.11765, with a high estimate of USD150 and a low estimate of USD25. 18 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +361.17% Upside potential.
What Is the JANX Premarket Price?
JANX's last pre-market stock price is 14.02. The pre-market share volume is 1,770.00, and the stock has decreased by -0.07, or -0.50%.
What Is the JANX After Hours Price?
JANX's last after hours stock price is 14.04, the stock has decreased by -0.08, or -0.57%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.